Open AccessApplication of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
Author(s) -
Tao You,
Weiguo Hu,
Xiaowen Ge,
Jingnan Shen,
Xuebin Qin
Publication year - 2011
Publication title -
cellular and molecular immunology/cellular and molecular immunology
Language(s) - English
Resource type - Journals
eISSN - 2042-0226
pISSN - 1672-7681
DOI - 10.1038/cmi.2010.35
Subject(s) - rituximab , cytolysis , cd59 , monoclonal antibody , cancer research , lymphoma , medicine , immunotherapy , complement dependent cytotoxicity , antibody , immunology , cytotoxicity , antibody dependent cell mediated cytotoxicity , complement system , chemistry , immune system , in vitro , biochemistry
Many monoclonal antibodies (mAbs) have been extensively used in the clinic, such as rituximab to treat lymphoma. However, resistance and non-responsiveness to mAb treatment have been challenging for this line of therapy. Complement is one of the main mediators of antibody-based cancer therapy via the complement-dependent cytolysis (CDC) effect. CD59 plays a critical role in resistance to mAbs through the CDC effect. In this paper, we attempted to investigate whether the novel CD59 inhibitor, recombinant ILYd4, was effective in enhancing the rituximab-mediated CDC effect on rituximab-sensitive RL-7 lymphoma cells and rituximab-induced resistant RR51.2 cells. Meanwhile, the CDC effects, which were mediated by rituximab and anti-CD24 mAb, on the refractory multiple myeloma (MM) cell line ARH-77 and the solid tumor osteosarcoma cell line Saos-2, were respectively investigated. We found that rILYd4 rendered the refractory cells sensitive to the mAb-mediated CDC effect and that rILYd4 exhibited a synergistic effect with the mAb that resulted in tumor cells lysis. This effect on tumor cell lysis was apparent on both hematological tumors and solid tumors. Therefore, rILYd4 may serve as an adjuvant for mAb mediated-tumor immunotherapy.